| 产品详情 |
| Edit |   |
|---|
| Antigenic Specificity | Siglec-2/CD22 |
|---|
| Clone | hL22 (Epratuzumab) |
|---|
| Host Species | Human |
|---|
| Reactive Species | human, cynomolgus monkey, rhesus macaque |
|---|
| Isotype | IgG1 kappa |
|---|
| Format | Protein A purified |
|---|
| Size | 0.2 mg |
|---|
| Concentration | n/a |
|---|
| Applications | Flow Cytometry, Immunoprecipitation, Block/Neutralize. Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010). |
|---|
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
|---|
| Description | The Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) from Novus Biologicals is a human monoclonal antibody to Siglec-2/CD22. This antibody reacts with human, cynomolgus monkey, rhesus macaque. The Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) has been validated for the following applications: Flow Cytometry, Immunoprecipitation, Block/Neutralize. This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells |
|---|
| Immunogen | This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010). |
|---|
| Other Names | B-cell receptor CD22, BL-CAM, B-lymphocyte cell adhesion molecule, CD22 antigenMGC130020, CD22 molecule, sialic acid binding Ig-like lectin 2, Sialic acid-binding Ig-like lectin 2, SIGLEC-2, SIGLEC2FLJ22814, T-cell surface antigen Leu-14 |
|---|
| Gene, Accession # | CD22, Gene ID: 933 |
|---|
| Catalog # | NBP2-75188 |
|---|
| Price | |
|---|
| Order / More Info | Siglec-2/CD22 Antibody from NOVUS BIOLOGICALS, LLC |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|